DNA icon

Ginkgo Bioworks

5.55 USD
-0.15
2.63%
Updated Apr 1, 3:29 PM EDT
1 day
-2.63%
5 days
-22.16%
1 month
-30.71%
3 months
-45.69%
6 months
-26.97%
Year to date
-45.69%
1 year
-87.61%
5 years
-98.86%
10 years
-98.86%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

290% more call options, than puts

Call options by funds: $29.6M | Put options by funds: $7.59M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]

49% more capital invested

Capital invested by funds: $215M [Q3] → $319M (+$104M) [Q4]

38% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 26

10.79% more ownership

Funds ownership: 61.13% [Q3] → 71.92% (+10.79%) [Q4]

5% more funds holding

Funds holding: 158 [Q3] → 166 (+8) [Q4]

8% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 39

Research analyst outlook

We haven’t received any recent analyst ratings for DNA.

Financial journalist opinion

Based on 5 articles about DNA published over the past 30 days

Neutral
Zacks Investment Research
4 hours ago
Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 Weeks
The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 Weeks
Neutral
Zacks Investment Research
4 days ago
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $6.59, denoting a -0.9% change from the preceding trading day.
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Positive
Zacks Investment Research
1 week ago
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.27, moving +1.39% from the previous trading session.
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing
Negative
Zacks Investment Research
2 weeks ago
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
Positive
Zacks Investment Research
3 weeks ago
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why
Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why
Negative
Seeking Alpha
1 month ago
Ginkgo Bioworks: Revenue Struggles Continue
Ginkgo Bioworks missed Q4 revenue estimates and issued extremely weak 2025 revenue guidance. Despite improving losses and cash burn, financial flexibility is decreasing, with cash reserves dropping significantly over the past year. The company's valuation is low, but declining revenues and high stock-based compensation pose risks.
Ginkgo Bioworks: Revenue Struggles Continue
Negative
Seeking Alpha
1 month ago
2025 Is Make Or Break For Ginkgo Bioworks
Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025. Unless Ginkgo can demonstrate continuous progress in 2025, its stock is likely to remain under pressure due to its shrinking cash runway.
2025 Is Make Or Break For Ginkgo Bioworks
Negative
Benzinga
1 month ago
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday.
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Neutral
Seeking Alpha
1 month ago
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q4 2024 Earnings Conference Call February 25, 2025 5:30 PM ET Company Participants Joseph Fridman - Director, Communications and Corporate Affairs Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Jason Kelly - Founder, CEO & Director Conference Call Participants Jason Lai - Morgan Stanley Evie Kslosky - Goldman Mark Massaro - BTIG Brendan Smith - TD Cowen Matt Larew - William Blair & Company Joseph Fridman Good evening. I'm Joseph Fridman, Director of Communications and Corporate Affairs here at Ginkgo, where it's my fifth year.
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $3.60 per share a year ago.
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates
Charts implemented using Lightweight Charts™